Bausch Health Companies Inc. is a diversified specialty pharmaceutical company headquartered in Laval, Quebec, Canada. Formerly known as Valeant Pharmaceuticals International, Inc., it develops, manufactures, and markets prescription and over-the-counter medicines as well as medical devices. Its portfolio is centered on eye health (through majority-owned Bausch + Lomb), gastroenterology (Salix), and dermatology, with products distributed in global healthcare and retail channels.
The company operates R&D, manufacturing, and distribution facilities across North America, Europe, Latin America, and Asia. Its operations include drug formulation, sterile and topical product manufacturing, and medical device production under international regulatory standards. Positioned at the interface of pharmaceuticals and healthcare-related materials and processes, Bausch Health contributes to supply chains relevant to ophthalmic, gastrointestinal, and dermatologic therapies.
Also known as Valeant Pharmaceuticals International, Inc. and Valeant.
Brett Icahn joins IFF's Audit and Transaction Committees, while Richard Mulligan joins the Innovation Committee, following a cooperation agreement with Icahn Capital.
